Evommune, Inc. (EVMN)
Evommune will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Company Description
Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis and ulcerative colitis.
Among our portfolio of programs, we currently have two product candidates, EVO756 and EVO301, in Phase 2 trials.
We are initially developing EVO756 for the treatment of CSU and AD, and EVO301 for the treatment of AD and UC.
We see broad expansion potential for both programs across additional chronic inflammatory diseases. We also intend to advance additional preclinical programs into clinical development.
Evommune, Inc.
| Country | United States |
| Founded | 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 45 |
| CEO | Luis Peña |
Contact Details
Address: 1841 Page Mill Road, Suite 100 Palo Alto, CA 94304 United States | |
| Phone | (925) 247-4487 |
| Website | evommune.com |
Stock Details
| Ticker Symbol | EVMN |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002044725 |
| Employer ID | 85-0742575 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Luis Peña | President & Chief Executive Officer and Director |
| Kyle Carver, M.B.A., C.P.A. | Chief Financial Officer |
| Eugene A. Bauer, M.D. | Chief Medical Officer and Director |
| Gregory S. Moss, Esq. | Chief Business and Legal Officer, Corporate Secretary and Chief Compliance Officer |
| Jeegar Patel, Ph.D. | Chief Scientific Officer |
| Janice Drew, M.P.H. | Executive Vice President, Operations |
| Benjamin F. McGraw, III, Pharma. D. | Director, Chairman of the Board |
| Francois Beaubien, Ph.D., C.F.A. | Director |
| David E. Cohen, M.D., M.P.H. | Director |
| Derek DiRocco, Ph.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 9, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Sep 23, 2025 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Sep 2, 2025 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jul 18, 2025 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| May 14, 2025 | DRS | [Cover] Draft Registration Statement |
| Jan 8, 2025 | D | Notice of Exempt Offering of Securities |
| Jan 8, 2025 | D | Notice of Exempt Offering of Securities |
| Jan 8, 2025 | D | Notice of Exempt Offering of Securities |
| Jan 7, 2025 | D | Notice of Exempt Offering of Securities |